RTGN 最新10-Q变化
将 RTGN 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-20
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +13 | −11 | ~8 | 35 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 4 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 部分风险因素更新 | 0 | 0 | ~4 | 4 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
The following table sets forth key components of our results of operations for the three months ended June 30, 2026 and 2025.
We did not recognize revenues for the three months ended June 30, 2026 and 2025.
Research and development expenses increased by $51,976, or 360%, to $66,406 for the three months ended June 30, 2026 from $14,430 for the three months ended June 30, 2025. The increase was primarily the result of engaging engineering and technology consultants to work on the RetinalCam project.
Stock-based compensation expenses decreased by $225,407 or 90%, to $24,782 for the three months ended June 30, 2026 from $250,189 for the three months ended June 30, 2025. The decrease was primarily due to the recognition of expense for options issued in the first quarter of 2025 and which had a sig…
General and administrative expenses decreased by $171,475 or 45%, to $212,254 for the three months ended June 30, 2026 from $383,729 for the three months ended June 30, 2025. Administrative costs consisting of costs related to the services provided by the executive from Sanovas, were allocated based…
相对上期删除的文字 · 来源:10-Q · 2026-05-20
We are actively pursuing our mission to prevent vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy, in ourfirst two devices:
We intend to launch RetinalCamTM in the fourth quarter of 2026.
Comparison of the three months ended March 31, 2026 and 2025
The following table sets forth key components of our results of operations for the three months ended March 31, 2026 and 2025.
We did not recognize revenues for the three months ended March 31, 2026 and 2025.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议